a·lac·ri·ty [uh-lak-ri-tee] cheerful readiness, promptness, or willingness
Europe: London BioScience Innovation Centre 2 Royal College Street London NW1 0NH
United Kingdom: Innovation Centre Unit 23, Cambridge Science Park CB4 0FN
USA: Cambridge Innovation Center 1 Broadway, 14th Floor Kendall Square, Cambridge MA 02142

changing the face
of life sciences consulting


Trusted people

Simon Turner

With experience as a management consultant, investor and biotech CEO, Simon advises on technology commercialisation and strategic development issues…

Read more »

Case studies

An ex-US business development strategy

Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded diagnostics company.

Read more »


Alacrita has substantial expertise in antibody discovery, development and commercialisation. We have helped a number of clients assess antibody opportunities, including target and technology assessment, strategic valuation and biosimilar market positioning...

Read more »

Antibodies to treat bacterial infections

Alacrita's antibody consultants conducted a review of the potential of modern antibody technologies to treat severe bacterial infections. Alacrita detailed the challenges involved, the types of target available and conducted a review of the industry's antibody pipeline. We conducted a SWOT analysis on monoclonal antibody technologies that the client had encountered with respect to their applicability to bacterial infections, with suggestions of other technologies that the company should consider.

Read more »

Biomarker identification technology

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of candidate therapeutic mAb targets and/or biomarkers...

Read more »

Board observer for private equity investor

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD discussions based on his industry expertise and strategic understanding gained through a long association with companies in similar stages of development.

Read more »